ClinicalTrials.gg
CompletedNCT00591773Updated Apr 19, 2011Results posted

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Azilsartan medoxomil and chlorthalidone in Hypertension, sponsored by Takeda. Completed at 46 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
551
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.

Enrollment
12th of 21
551 · median 566
Started
2007
with 6 others
Phase 3
17 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
19 of 21
Takeda

Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 12th largest by enrollment, is one of 7 that started in 2007, is one of 17 in phase 3, and was the 2nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing azilsartan medoxomil in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone.

Read the detailed description

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.

TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker that was shown to be a orally active antihypertensive agent with a prolonged duration of activity and good safety tolerability in a recent clinical study. Chlorthalidone is a thiazide-like diuretic that reduces blood pressure by decreasing intravascular volume through urinary salt and water excretion. By combining this action with azilsartan medoxomil, a greater reduction in blood pressure is expected than with either agent alone. For subjects requiring combination therapy, azilsartan medoxomil plus chlorthalidone offers a novel combination that may provide a more potent and safe combination for blood pressure reduction.

This study is being conducted to determine whether administration of azilsartan medoxomil in combination with chlorthalidone to subjects with uncontrolled hypertension is more effective in reducing blood pressure than chlorthalidone alone. This study is also being conducted to evaluate the safety and tolerability of azilsartan medoxomil combined with chlorthalidone.

Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be about 10 Weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs including sitting and standing blood pressure and pulse, body height and weight, physical examinations, electrocardiogram. Outside of the study center, participants will be required to wear an ambulatory blood pressure monitoring device at 24 hour intervals.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Blood pressure
  • Blood pressure monitoring, ambulatory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has essential hypertension (defined as sitting trough clinic systolic blood pressure between 160 and 190 mm Hg inclusive at Day minus 1 and 24-hour mean systolic blood pressure greater than or equal to 140 mm Hg and ≤ 180 mm Hg at Day 1).
  2. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  3. Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or results that are deemed not for inclusion into this study by the investigator.
  4. Willing to discontinue current antihypertensive medications at the Screening Day minus 21 visit. If the subject is on amlodipine prior to screening, the subject is willing to discontinue this medication at Screening Day minus 28.

Exclusion criteria

Exclusion Criteria

  1. Has sitting trough clinic diastolic blood pressure greater than 119 mmHg at Day minus 1.
  2. Has a baseline 24 hour ambulatory blood pressure monitor reading of insufficient quality.
  3. Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.
  4. Recent history (within the last 6 months) of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  5. cardiac conduction defects (for example, 3rd degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation).
  6. Hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  7. The subject has secondary hypertension of any etiology.
  8. Non-compliant (less than 70% or greater than 130%) with study medication
  9. during the placebo run- in period.
  10. Severe renal dysfunction or disease (based on calculated less than 30 mL/min/1.73 m2) at Screening.
  11. Known or suspected unilateral or bilateral renal artery stenosis.
  12. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic drinks per day) within the past 2 years.
  13. Previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those subjects with basal cell or Stage 1 squamous cell carcinoma of the skin.)
  14. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated greater than 8.0%).
  15. Hypo- or hyperkalemia (defined as serum potassium outside of the normal reference range of the central laboratory).
  16. level of greater than 2.5 times the , active liver disease, or jaundice.
  17. Upper arm circumference less than 24 cm or greater than 42 cm.
  18. Works night (3rd) shift (defined as 11PM [2300] to 7AM [0700]).
  19. Currently is participating in another study or has participated in an investigational study within 30 days prior to randomization.
  20. Study site employee, or is an immediate family member ( ie, spouse, parent, child, sibling) of a study site employee who is involved in conduct of this study.
  21. Any other serious disease or condition at Screening (or Randomization) that would compromise subject safety, might affect , or make it difficult to successfully manage and follow the subject according to the protocol.
  22. Randomized in a previous azilsartan medoxomil study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
551 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Experimental
    Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD

    Drug: Azilsartan medoxomil and chlorthalidone

  • Active comparator
    Chlorthalidone 25 mg QD

    Drug: Chlorthalidone

Interventions

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.

    Also known as: TAK-491, Edarbi

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.

    Also known as: TAK-491, Edarbi

  • Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.

    Also known as: Thalitone

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6.

Secondary outcomes

  1. Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

    The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  2. Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6.

  3. Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure.

    The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  4. Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 6.

  5. Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 6.

  6. Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 6.

  7. Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 6.

  8. Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 6.

  9. Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 6.

  10. Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 6.

  11. Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 6.

  12. Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

    Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  13. Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

    Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6 , defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  14. Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.

    Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

    Time frame: Baseline and Week 6.

07

Results

Posted Apr 19, 2011

Participant flow

Participants enrolled at 74 investigative sites in Argentina, Chile, Mexico, Peru and the United States from 07 September 2007 to 05 March 2009.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Started185182184
Completed169158168
Not completed162416
Withdrew: Adverse event996
Withdrew: Protocol violation230
Withdrew: Lost to follow-up141
Withdrew: Withdrawal by subject253
Withdrew: Lack of efficacy122
Withdrew: Other114

Outcome measures

PrimaryChange From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-31.72 ± 0.966-31.30 ± 0.973-15.85 ± 0.957
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.) · Mean difference (final values): -15.86 · 95% CI -18.54 to -13.19
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.) · Mean difference (final values): -15.45 · 95% CI -18.13 to -12.76
SecondaryChange From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.-36.16 ± 1.226-34.44 ± 1.236-21.76 ± 1.229
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.) · Mean difference (final values): -14.40 · 95% CI -17.81 to -10.99
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.) · Mean difference (final values): -12.68 · 95% CI -16.10 to -9.25
SecondaryChange From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-18.28 ± 0.626-18.49 ± 0.630-7.99 ± 0.619
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.29 · 95% CI -12.02 to -8.56
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -10.49 · 95% CI -12.23 to -8.76
SecondaryChange From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure.

The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure.-16.18 ± 0.717-15.98 ± 0.723-8.93 ± 0.719
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.25 · 95% CI -9.25 to -5.25
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.05 · 95% CI -9.06 to -5.05
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-32.53 ± 0.996-31.97 ± 1.003-15.73 ± 0.988
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -16.80 · 95% CI -19.56 to -14.04
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -16.24 · 95% CI -19.01 to -13.47
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-18.82 ± 0.665-18.99 ± 0.670-7.79 ± 0.659
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.02 · 95% CI -12.86 to -9.18
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.20 · 95% CI -13.04 to -9.35
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-29.52 ± 1.080-29.43 ± 1.087-16.59 ± 1.069
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.93 · 95% CI -15.92 to -9.94
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.84 · 95% CI -15.83 to -9.84
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-17.05 ± 0.714-17.06 ± 0.718-8.89 ± 0.707
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.16 · 95% CI -10.14 to -6.19
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.17 · 95% CI -10.15 to -6.19
SecondaryChange From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-33.02 ± 1.039-32.45 ± 1.048-15.50 ± 1.031
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -17.52 · 95% CI -20.39 to -14.64
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -16.95 · 95% CI -19.84 to -14.05
SecondaryChange From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-19.06 ± 0.706-19.20 ± 0.710-7.53 ± 0.698
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.54 · 95% CI -13.49 to -9.59
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.68 · 95% CI -13.64 to -9.72
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-30.73 ± 1.118-30.16 ± 1.126-16.69 ± 1.108
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -14.04 · 95% CI -17.13 to -10.94
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -13.48 · 95% CI -16.58 to -10.37
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-18.78 ± 0.804-19.04 ± 0.810-9.36 ± 0.797
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.42 · 95% CI -11.65 to -7.20
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.69 · 95% CI -11.92 to -7.46
SecondaryPercentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
percentage of participantsAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg87.784.163.5
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 4.09 · 95% CI 2.38 to 7.03
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.03 · 95% CI 1.82 to 5.03
SecondaryPercentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6 , defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
percentage of participantsAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg92.790.378.1
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · Regression, Logistic · p = <0.001 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.72 · 95% CI 1.90 to 7.27
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · Regression, Logistic · p = 0.002 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 2.70 · 95% CI 1.46 to 5.00
SecondaryPercentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.
percentage of participantsAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.84.980.758.4
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 4.00 · 95% CI 2.41 to 6.64
  • Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD vs Chlorthalidone 25 mg QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 2.96 · 95% CI 1.83 to 4.79

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD—3/184 (1.6%)34/184 (18.5%)
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD—3/182 (1.6%)31/182 (17%)
Chlorthalidone 25 mg QD—1/181 (0.6%)29/181 (16%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
Cardiac failureCardiac disorders0/1840/1821/181
Cardiogenic shockCardiac disorders0/1840/1821/181
PneumoniaInfections and infestations0/1840/1821/181
Urinary tract infectionInfections and infestations0/1841/1820/181
Jaw fractureInjury, poisoning and procedural complications0/1841/1820/181
Skin lacerationInjury, poisoning and procedural complications0/1841/1820/181
SyncopeNervous system disorders1/1841/1820/181
Lacunar infarctionNervous system disorders0/1841/1820/181
Atrioventricular block completeCardiac disorders1/1840/1820/181
Chest discomfortGeneral disorders1/1840/1820/181
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QD
DizzinessNervous system disorders16/18419/1826/181
HeadacheNervous system disorders8/1849/18213/181
Plasminogen activator inhibitor increasedInvestigations12/1844/1823/181
HypokalaemiaMetabolism and nutrition disorders2/1844/18211/181

Baseline characteristics

Age Categorical
Age Categorical(participants)Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QDTotal
<45 years21151652
Between 45 and 64 years114110113337
≥65 years505755162
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QDAzilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QDChlorthalidone 25 mg QDTotal
Female968882266
Male8994102285
08

Study locations

46 sites
  • Huntsville, Alabama, United States
  • Montgomery, Alabama, United States
  • Buena Park, California, United States
  • Huntington Beach, California, United States
  • Long Beach, California, United States
  • Mission Viejo, California, United States
  • Roseville, California, United States
  • Sacramento, California, United States
  • Westlake Village, California, United States
  • Coral Gables, Florida, United States
  • Deland, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Hollywood, Florida, United States
  • Miami, Florida, United States
  • Auburn, Maine, United States
  • Bingham Farms, Michigan, United States
  • Troy, Michigan, United States
  • Charlotte, North Carolina, United States
  • Huntersville, North Carolina, United States
  • Shelby, North Carolina, United States
  • Akron, Ohio, United States
  • Centerville, Ohio, United States
  • Cincinnati, Ohio, United States
  • Willoughby Hills, Ohio, United States
  • Zanesville, Ohio, United States
  • Norman, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • Tualatin, Oregon, United States
  • Bensalem, Pennsylvania, United States
  • Feasterville, Pennsylvania, United States
  • Cranston, Rhode Island, United States
  • Simpsonville, South Carolina, United States
  • Kingsport, Tennessee, United States
  • Corpus Christi, Texas, United States
  • Houston, Texas, United States
  • Pearland, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Arlington, Virginia, United States
  • Burke, Virginia, United States
  • Richmond, Virginia, United States
  • Lakewood, Washington, United States
  • Olympia, Washington, United States
  • Port Orchard, Washington, United States
09

References and documents

Publications

  • Weber MA, Sever P, Juhasz A, Roberts A, Cao C. A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone. J Renin Angiotensin Aldosterone Syst. 2018 Jul-Sep;19(3):1470320318795000. doi: 10.1177/1470320318795000. PubMed 30175930 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2007
First posted
Jan 11, 2008
Start
Sep 2007
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Apr 19, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00591773
Lead sponsor
Takeda
First posted
Jan 11, 2008
Start date
Sep 2007
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Apr 19, 2011
Last update
Apr 19, 2011

Study contacts

Executive Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone

Start the discussion